These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721 [TBL] [Abstract][Full Text] [Related]
7. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score. Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783 [TBL] [Abstract][Full Text] [Related]
8. Growth hormone in sports: detecting the doped or duped. Ho KK; Nelson AE Horm Res Paediatr; 2011; 76 Suppl 1():84-90. PubMed ID: 21778756 [TBL] [Abstract][Full Text] [Related]
9. The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes. Erotokritou-Mulligan I; Bassett EE; Bartlett C; Cowan D; McHugh C; Seah R; Curtis B; Wells V; Harrison K; Sönksen PH; Holt RI; J Clin Endocrinol Metab; 2008 Jul; 93(7):2760-3. PubMed ID: 18413420 [TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection. Guha N; Cowan DA; Sönksen PH; Holt RI Anal Bioanal Chem; 2013 Dec; 405(30):9669-83. PubMed ID: 23934394 [TBL] [Abstract][Full Text] [Related]
11. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199 [TBL] [Abstract][Full Text] [Related]
12. A robust test for growth hormone doping--present status and future prospects. Nelson AE; Ho KK Asian J Androl; 2008 May; 10(3):416-25. PubMed ID: 18385903 [TBL] [Abstract][Full Text] [Related]
13. Growth hormone, IGF-I and insulin and their abuse in sport. Holt RI; Sönksen PH Br J Pharmacol; 2008 Jun; 154(3):542-56. PubMed ID: 18376417 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors. Okano M; Nishitani Y; Sato M; Kageyama S Drug Test Anal; 2012 Sep; 4(9):692-700. PubMed ID: 22733714 [TBL] [Abstract][Full Text] [Related]
15. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex. Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087 [TBL] [Abstract][Full Text] [Related]
16. The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. Holt RI; Erotokritou-Mulligan I; McHugh C; Bassett EE; Bartlett C; Fityan A; Bacon JL; Cowan DA; Sönksen PH Eur J Endocrinol; 2010 Jul; 163(1):45-54. PubMed ID: 20421332 [TBL] [Abstract][Full Text] [Related]
17. The effects of two weeks of recombinant growth hormone administration on the response of IGF-I and N-terminal pro-peptide of collagen type III (P-III-NP) during a single bout of high resistance exercise in resistance trained young men. Velloso CP; Aperghis M; Godfrey R; Blazevich AJ; Bartlett C; Cowan D; Holt RI; Bouloux P; Harridge SD; Goldspink G Growth Horm IGF Res; 2013 Jun; 23(3):76-80. PubMed ID: 23433656 [TBL] [Abstract][Full Text] [Related]
18. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773 [TBL] [Abstract][Full Text] [Related]
19. Biomarker detection of rhGH doping: an excretion study. Jing J; Zhou X; He C; Zhang L; Yang S; Xu Y; Xie M; Yan Y; Su H; Wu M Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170 [TBL] [Abstract][Full Text] [Related]
20. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant growth hormone misuse: insulin-like growth factor I and procollagen type III peptide. Abellan R; Ventura R; Pichini S; Di Giovannandrea R; Bellver M; Olive R; Pacifici R; Pascual JA; Zuccaro P; Segura J Int J Sports Med; 2006 Dec; 27(12):976-83. PubMed ID: 16612742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]